Author:
Nayımoğlu Mehmet,Sarıfakıoğlu Banu,Ustaömer Kübra,Akgül Murat,Isal Arslan Ayşegül
Abstract
Infliximab is an inhibitory of tumor necrosis factor-alpha which is used successfully for the treatment of inflammatory bowel disease and rheumatic disease. It has various side effects including injection-induced reactions, immunosuppression, demyelinating diseases, and cardiac effects. One of the most serious side effects is tuberculosis. In particular, the immunosuppressant drugs have a high risk of reactivating latent tuberculosis infection. Its activation probably may occur as an extra-pulmonary and, occasionally, may result in an unusual infection. Herein, we report a 30-year-old male case treated with infliximab and suffered from isolated testicular tuberculosis.
Publisher
Baycinar Tibbi Yayincilik
Subject
Rehabilitation,Physical Therapy, Sports Therapy and Rehabilitation
Reference16 articles.
1. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005;44:714-20.
2. Beenhouwer D, Wallis R, Broder M, Furst DE. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol 2004;31:1888-92.
3. PAY S. Romatizmal Hastalıklarda Anti-TNF ilaç kullanımı. Türkiye Klinikleri Tıp Bilimleri Dergisi 2006;26:430-40.
4. Drudi FM, Laghi A, Iannicelli E, Di Nardo R, Occhiato R, Poggi R, et al. Tubercular epididymitis and orchitis: US patterns. Eur Radiol 1997;7:1076-8.
5. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(5 Suppl1):34-8.